Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

NCT05952934 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

BIOLOGICAL: 0.5 mL Candin®/injection
OTHER: Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)

Sponsor

University of Arkansas

Collaborators

[object Object]
[object Object]